Aleece MacPhail
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aleece MacPhail has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
Stephan Harbarth
Infection Control Program and WHO Collaborating Centre, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
3 shared publications- Zoe K. McQuilten
Transfusion Research Unit, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia
3 shared publications Aude Nguyen
Infection Control Program and WHO Collaborating Centre, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
2 shared publications- Bryan Tan
Monash Infectious Diseases Monash Health Melbourne Victoria Australia
2 shared publications Claire Dendle
Faculty of Medicine Nursing and Health Science Monash University Clayton Victoria Australia
2 shared publications- Claire Dendle
Centre for Inflammatory Diseases, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia
2 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Springer Nature in Current Fungal Infection Reports
- Vol. 20 (1) , 25
Pneumocystis jirovecii Pneumonia in Haematology Patients Treated with Bispecific Antibodies, CAR-T Cell Therapy and Targeted Small Molecules
Purpose of Review: With the expansion of new targeted and immune-based therapies, there is increased uncertainty regarding Pneumocystis jirovecii pneumonia (PJP) risk and use of prophylaxis. Bispecific antibodies, chimeric antigen receptor (CAR)-T cell therapy, B-cell lymphoma-2 (BCL-2) inhibitors and Bruton tyrosine kinase (BTK) inhibitors cause distinct immune deficits. Determining PJP risk in patients treated with these agents is important to inform evidence-based prophylaxis strategies. Recent Findings: PJP risk is infrequently and incompletely described in early clinical trials of novel therapies for haematological malignancies. Although observational studies and case series highlight the need for ongoing surveillance and consistent reporting of prophylaxis use and PJP events, it is essential to define treatment-associated risk and inform the role of routine PJP prophylaxis in clinical practice. Current guidelines are based on limited evidence and inconsistencies in guideline recommendations further contribute to variability in prophylaxis practices. Summary: Despite the rapid increase in clinical exposures to bispecific antibodies, CAR-T cell therapies, BCL-2 inhibitors and BTK inhibitors, the magnitude and timing of PJP risk remains uncertain. PJP risk is high in recipients of CAR-T cell therapy, for whom routine prophylaxis is recommended; moderate and frequently reported in recipients of bispecific antibodies; and low to variable in recipients of BTK and BCL-2 inhibitors, respectively, for whom prophylaxis is generally reserved for those with additional risk factors. Prospective studies with standardised PJP surveillance and prophylaxis reporting are required to define high-risk populations and periods of vulnerability, enabling risk-stratification prophylaxis recommendations that balance PJP prevention against toxicity and treatment burden.
- 5 November 2026
- Published by Springer Nature in Current Fungal Infection Reports
- Vol. 20 (1) , 25
Open AccessPneumocystis jirovecii Pneumonia in Haematology Patients Treated with Bispecific Antibodies, CAR-T Cell Therapy and Targeted Small Molecules
Purpose of Review: With the expansion of new targeted and immune-based therapies, there is increased uncertainty regarding Pneumocystis jirovecii pneumonia (PJP) risk and use of prophylaxis. Bispecific antibodies, chimeric antigen receptor (CAR)-T cell therapy, B-cell lymphoma-2 (BCL-2) inhibitors and Bruton tyrosine kinase (BTK) inhibitors cause distinct immune deficits. Determining PJP risk in patients treated with these agents is important to inform evidence-based prophylaxis strategies. Recent Findings: PJP risk is infrequently and incompletely described in early clinical trials of novel therapies for haematological malignancies. Although observational studies and case series highlight the need for ongoing surveillance and consistent reporting of prophylaxis use and PJP events, it is essential to define treatment-associated risk and inform the role of routine PJP prophylaxis in clinical practice. Current guidelines are based on limited evidence and inconsistencies in guideline recommendations further contribute to variability in prophylaxis practices. Summary: Despite the rapid increase in clinical exposures to bispecific antibodies, CAR-T cell therapies, BCL-2 inhibitors and BTK inhibitors, the magnitude and timing of PJP risk remains uncertain. PJP risk is high in recipients of CAR-T cell therapy, for whom routine prophylaxis is recommended; moderate and frequently reported in recipients of bispecific antibodies; and low to variable in recipients of BTK and BCL-2 inhibitors, respectively, for whom prophylaxis is generally reserved for those with additional risk factors. Prospective studies with standardised PJP surveillance and prophylaxis reporting are required to define high-risk populations and periods of vulnerability, enabling risk-stratification prophylaxis recommendations that balance PJP prevention against toxicity and treatment burden.
- 3 July 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (3) , 411-418
Reconsidering ambiguous language in infectious disease consult recommendations
Background: Infectious diseases (ID) consultations are associated with improved patient outcomes. We aimed to determine whether ambiguous language affects adherence to recommendations. Methods: We conducted a retrospective study of consecutive ID consultations across four campuses of a 2,500 bed hospital network in 2024. Ambiguous language use was quantified and described. The relationship between ambiguous language and adherence to recommendations was assessed using univariable and multivariable mixed effects logistic regression, with consult episode as a random effect. Other predictors of ambiguous language and adherence were assessed and adjusted for, including referring unit, consulting team demographics, recommendation type and number of recommendations. Results: 1087 recommendations were made across 250 consecutive consultations. Of these, 106/1087 (9.8%) used ambiguous language, most commonly the expression “consider”. Adherence was assessable in 977/1087 recommendations. Adherence to assessable non-ambiguous recommendations was 87.2% (725/903 [80.3%] completely followed, 62/903 [6.9%] partially followed), while adherence to ambiguous recommendations was 59.5% (38/74 [51.4%] totally followed, 6/74 [8.1%] partially followed, p <0.001). In multivariable analysis, recommendations containing ambiguous language were significantly less likely to be followed (adjusted OR 0.16, 95% CI 0.09-0.30, p < 0.001). Other significant predictors of adherence were therapeutic recommendation, and consultant seniority. There was no association between adherence and clinician gender, referring unit, or total number of recommendations. Use of ambiguous language was more frequent in recommendations that were not immediately actionable. Conclusion: Ambiguous language in ID consults is frequent, and is associated with reduced adherence to recommendations.
- 3 July 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (3) , 411-418
Reconsidering ambiguous language in infectious disease consult recommendations
Background: Infectious diseases (ID) consultations are associated with improved patient outcomes. We aimed to determine whether ambiguous language affects adherence to recommendations. Methods: We conducted a retrospective study of consecutive ID consultations across four campuses of a 2,500 bed hospital network in 2024. Ambiguous language use was quantified and described. The relationship between ambiguous language and adherence to recommendations was assessed using univariable and multivariable mixed effects logistic regression, with consult episode as a random effect. Other predictors of ambiguous language and adherence were assessed and adjusted for, including referring unit, consulting team demographics, recommendation type and number of recommendations. Results: 1087 recommendations were made across 250 consecutive consultations. Of these, 106/1087 (9.8%) used ambiguous language, most commonly the expression “consider”. Adherence was assessable in 977/1087 recommendations. Adherence to assessable non-ambiguous recommendations was 87.2% (725/903 [80.3%] completely followed, 62/903 [6.9%] partially followed), while adherence to ambiguous recommendations was 59.5% (38/74 [51.4%] totally followed, 6/74 [8.1%] partially followed, p <0.001). In multivariable analysis, recommendations containing ambiguous language were significantly less likely to be followed (adjusted OR 0.16, 95% CI 0.09-0.30, p < 0.001). Other significant predictors of adherence were therapeutic recommendation, and consultant seniority. There was no association between adherence and clinician gender, referring unit, or total number of recommendations. Use of ambiguous language was more frequent in recommendations that were not immediately actionable. Conclusion: Ambiguous language in ID consults is frequent, and is associated with reduced adherence to recommendations.
- Open Access
- 12 February 2026
- Published by Wiley in British Journal of Haematology
- Vol. 208 (3) , 981-991
Prevention and management of febrile neutropenia in acute myeloid leukaemia and higher risk myelodysplastic syndrome: An international survey of current practice
Summary: Febrile neutropenia causes substantial morbidity in acute myeloid leukaemia and higher risk myelodysplastic syndrome. We aimed to describe current practice and priorities for clinical trials in the prevention and management of febrile neutropenia across Australia/New Zealand (ANZ), the United Kingdom (UK), Canada and Europe. We performed an international survey of haematologists recruited via professional networks. Eighty‐five unique hospitals were represented (ANZ = 20; Canada = 14; UK = 30; Europe = 21). Antibacterial prophylaxis was more commonly prescribed in Canada (79%) and the UK (83%) than in ANZ (30%) and Europe (48%, p < 0.001), and was prescribed more frequently to outpatients than inpatients. The most common empiric treatment was piperacillin–tazobactam monotherapy (66/84, 79%), with nurse‐initiated antibiotic orders used in 35/84 (42%). Screening for multidrug‐resistant organisms varied and was not usually used to direct antibiotic treatment. Antibiotic de‐escalation was attempted in most institutions; for uncomplicated short‐lived fever of unknown source, 39/85 (46%) reported ceasing antibiotics at 72 h and 68/85 (80%) within 7 days. For patients with bacteraemia, de‐escalation strategies included narrowing spectrum, oral switch and cessation after defined duration. Most respondents (79/85, 93%) reported interest in recruiting for clinical trials. Clinical trials addressing practice variability in febrile neutropenia are needed, and are supported by haematologists.
- 12 February 2026
- Published by Wiley in British Journal of Haematology
- Vol. 208 (3) , 981-991
Open AccessPrevention and management of febrile neutropenia in acute myeloid leukaemia and higher risk myelodysplastic syndrome: An international survey of current practice
Summary: Febrile neutropenia causes substantial morbidity in acute myeloid leukaemia and higher risk myelodysplastic syndrome. We aimed to describe current practice and priorities for clinical trials in the prevention and management of febrile neutropenia across Australia/New Zealand (ANZ), the United Kingdom (UK), Canada and Europe. We performed an international survey of haematologists recruited via professional networks. Eighty‐five unique hospitals were represented (ANZ = 20; Canada = 14; UK = 30; Europe = 21). Antibacterial prophylaxis was more commonly prescribed in Canada (79%) and the UK (83%) than in ANZ (30%) and Europe (48%, p < 0.001), and was prescribed more frequently to outpatients than inpatients. The most common empiric treatment was piperacillin–tazobactam monotherapy (66/84, 79%), with nurse‐initiated antibiotic orders used in 35/84 (42%). Screening for multidrug‐resistant organisms varied and was not usually used to direct antibiotic treatment. Antibiotic de‐escalation was attempted in most institutions; for uncomplicated short‐lived fever of unknown source, 39/85 (46%) reported ceasing antibiotics at 72 h and 68/85 (80%) within 7 days. For patients with bacteraemia, de‐escalation strategies included narrowing spectrum, oral switch and cessation after defined duration. Most respondents (79/85, 93%) reported interest in recruiting for clinical trials. Clinical trials addressing practice variability in febrile neutropenia are needed, and are supported by haematologists.
- Open Access
- 10 February 2026
- Published by Therapeutic Guidelines Limited in Australian Prescriber
- Vol. 49 (1) , 22-29
Preventing infections in immunosuppressed patients
Patients receiving immunosuppressive therapy are at increased risk of infection. This article outlines practical strategies to reduce infection risk, including risk assessment, targeted screening investigations, antimicrobial prophylaxis, vaccination and patient education.
- 10 February 2026
- Published by Therapeutic Guidelines Limited in Australian Prescriber
- Vol. 49 (1) , 22-29
Open AccessPreventing infections in immunosuppressed patients
Patients receiving immunosuppressive therapy are at increased risk of infection. This article outlines practical strategies to reduce infection risk, including risk assessment, targeted screening investigations, antimicrobial prophylaxis, vaccination and patient education.
- Open Access
- 19 January 2026
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (2)
Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome?
Long-acting glycopeptide antibiotics (LGPs), such as dalbavancin and oritavancin, are a novel class of antibiotic agents effective in the treatment of Gram-positive infections. The long half-life and relative ease of administration of LGPs make them a valuable treatment option for patients experiencing barriers to healthcare access. However, challenges for effective use remain, and disproportionately affect patients who would most benefit. These include high upfront costs, cost siloing, impractical and inconsistent medication approval processes and limited integration into existing multidisciplinary models of care. There is a clear need to improve funding arrangements, institutional workflows and models of care to promote safe and equitable access to LGPs, in line with processes developed for other high-cost medications.
- 19 January 2026
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (2)
Open AccessLong-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome?
Long-acting glycopeptide antibiotics (LGPs), such as dalbavancin and oritavancin, are a novel class of antibiotic agents effective in the treatment of Gram-positive infections. The long half-life and relative ease of administration of LGPs make them a valuable treatment option for patients experiencing barriers to healthcare access. However, challenges for effective use remain, and disproportionately affect patients who would most benefit. These include high upfront costs, cost siloing, impractical and inconsistent medication approval processes and limited integration into existing multidisciplinary models of care. There is a clear need to improve funding arrangements, institutional workflows and models of care to promote safe and equitable access to LGPs, in line with processes developed for other high-cost medications.
- Open Access
- 20 October 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (20) , 5367-5377
Immunoglobulin use, survival, and infection outcomes in patients with chronic lymphocytic leukemia
Patients with chronic lymphocytic leukemia (CLL) often experience infections due to immune suppression and/or dysregulation. Hypogammaglobulinemia is a key contributor to immunosuppression in CLL, and immunoglobulin replacement therapy (IgRT) is commonly given to prevent infections. However, the benefit of IgRT in preventing serious infections in CLL remains unclear. This study aimed to describe IgRT treatment patterns in a large, real-world cohort of patients with CLL, and explore the association between IgRT and serious infections. We conducted a retrospective longitudinal study of linked hospital data, including 6217 patients with CLL between 2008 and 2022 in Victoria, Australia. Kaplan-Meier survival analyses were performed to estimate survival, infection incidence, and IgRT use. Cox survival analyses explored associations between infections and IgRT in patients receiving regular prophylactic IgRT. Over the 14-year follow-up, the monthly proportion of patients experiencing serious infections doubled, while the proportion of patients receiving any IgRT quadrupled. The median time to death from CLL diagnosis was 10 years, and patients with serious infections had a higher mortality rate (0.090 [95% confidence interval (CI), 0.074-0.110]) vs those without (0.008 [95% CI, 0.007-0.009]). In total, 753 patients (12.1%) received IgRT, and 524 (8.4%) received IgRT regularly. In patients who received regular IgRT, infection incidence was higher during periods of IgRT (0.056 [95% CI, 0.052-0.060]) compared with periods without IgRT (0.038 [95% CI, 0.035-0.042]). Serious infections were associated with not only IgRT initiation and reinitiation, but also cessation. Further research is needed to evaluate the causal relationship between IgRT and infections in this population.
- 20 October 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (20) , 5367-5377
Open AccessImmunoglobulin use, survival, and infection outcomes in patients with chronic lymphocytic leukemia
Patients with chronic lymphocytic leukemia (CLL) often experience infections due to immune suppression and/or dysregulation. Hypogammaglobulinemia is a key contributor to immunosuppression in CLL, and immunoglobulin replacement therapy (IgRT) is commonly given to prevent infections. However, the benefit of IgRT in preventing serious infections in CLL remains unclear. This study aimed to describe IgRT treatment patterns in a large, real-world cohort of patients with CLL, and explore the association between IgRT and serious infections. We conducted a retrospective longitudinal study of linked hospital data, including 6217 patients with CLL between 2008 and 2022 in Victoria, Australia. Kaplan-Meier survival analyses were performed to estimate survival, infection incidence, and IgRT use. Cox survival analyses explored associations between infections and IgRT in patients receiving regular prophylactic IgRT. Over the 14-year follow-up, the monthly proportion of patients experiencing serious infections doubled, while the proportion of patients receiving any IgRT quadrupled. The median time to death from CLL diagnosis was 10 years, and patients with serious infections had a higher mortality rate (0.090 [95% confidence interval (CI), 0.074-0.110]) vs those without (0.008 [95% CI, 0.007-0.009]). In total, 753 patients (12.1%) received IgRT, and 524 (8.4%) received IgRT regularly. In patients who received regular IgRT, infection incidence was higher during periods of IgRT (0.056 [95% CI, 0.052-0.060]) compared with periods without IgRT (0.038 [95% CI, 0.035-0.042]). Serious infections were associated with not only IgRT initiation and reinitiation, but also cessation. Further research is needed to evaluate the causal relationship between IgRT and infections in this population.
- 4 July 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (1) , 93-99
Outcomes of Critical Illness in People With Advanced HIV Disease: 30 Years of Binational Data
Background: Before the advent of effective antiretroviral therapy, intensive care unit (ICU) admission rates for people with advanced human immunodeficiency virus HIV disease (AHD) were low, reflecting high mortality and limited treatment options. Despite improvements in ICU and HIV care, longitudinal outcome data in critically ill people with AHD are limited. Methods: We performed a retrospective cohort study of ICU admissions in Australia and New Zealand between January 1993 and December 2022 in patients with a comorbid diagnosis of AHD. AHD was defined according to Acute Physiology and Chronic Health Assessment-IIIj (APACHE-IIIj), requiring an HIV diagnosis plus AHD-defining complication. Descriptive analysis was performed. Longitudinal changes in mortality were reported. Admissions were stratified by decade. Results: There were 1505 ICU admissions with comorbid AHD over the study period. Between the first and third decades, the Sequential Organ Failure Score increased (median 3, interquartile range [IQR] 2–5 vs median 4, IQR 2–6, P < .001), as did patient age (median 41 years, IQR 34–52 vs median 53 years, IQR 44–63, P < .001). The proportion of patients with 1 or more chronic comorbidities using APACHE-IIIj scoring increased over time (18% vs 26%; P = .009). Crude hospital mortality reduced significantly from 36% in 1993–2002 to 14% in 2013–2022 (P < .001). Mortality improvements remained significant after adjustment for acute and chronic illness severity (using APACHE-IIIj risk of death) and hospital type (adjusted odds ratio of death by decade 0.43; 95% confidence interval, .35–.53). Conclusions: Despite advances in HIV care, a subset of people with AHD require ICU admission. Mortality in this group has improved by more than 50%.
- 4 July 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (1) , 93-99
Outcomes of Critical Illness in People With Advanced HIV Disease: 30 Years of Binational Data
Background: Before the advent of effective antiretroviral therapy, intensive care unit (ICU) admission rates for people with advanced human immunodeficiency virus HIV disease (AHD) were low, reflecting high mortality and limited treatment options. Despite improvements in ICU and HIV care, longitudinal outcome data in critically ill people with AHD are limited. Methods: We performed a retrospective cohort study of ICU admissions in Australia and New Zealand between January 1993 and December 2022 in patients with a comorbid diagnosis of AHD. AHD was defined according to Acute Physiology and Chronic Health Assessment-IIIj (APACHE-IIIj), requiring an HIV diagnosis plus AHD-defining complication. Descriptive analysis was performed. Longitudinal changes in mortality were reported. Admissions were stratified by decade. Results: There were 1505 ICU admissions with comorbid AHD over the study period. Between the first and third decades, the Sequential Organ Failure Score increased (median 3, interquartile range [IQR] 2–5 vs median 4, IQR 2–6, P < .001), as did patient age (median 41 years, IQR 34–52 vs median 53 years, IQR 44–63, P < .001). The proportion of patients with 1 or more chronic comorbidities using APACHE-IIIj scoring increased over time (18% vs 26%; P = .009). Crude hospital mortality reduced significantly from 36% in 1993–2002 to 14% in 2013–2022 (P < .001). Mortality improvements remained significant after adjustment for acute and chronic illness severity (using APACHE-IIIj risk of death) and hospital type (adjusted odds ratio of death by decade 0.43; 95% confidence interval, .35–.53). Conclusions: Despite advances in HIV care, a subset of people with AHD require ICU admission. Mortality in this group has improved by more than 50%.
- Open Access
- 9 April 2025
- Published by Springer Nature in Infection
- Vol. 53 (5) , 1-11
Epidemiology of hospital-acquired bloodstream infections in haemato-oncology patients in Geneva, Switzerland
Background: Hospital-acquired bloodstream infections (HA-BSI), including catheter-associated bloodstream infections (CABSI), cause preventable harm in haemato-oncology patients but surveillance data are limited. Methods: We performed a retrospective cohort study using prospectively collected data in a large hospital network in Switzerland from 2017–2022. Incidence, source, and microbiology of HA-BSI were compared between (1) haematology patients with acute leukaemia or allogeneic stem cell transplantation (2) oncology patients with solid tumour or lymphoma, and (3) general medical patients. No routine quinolone prophylaxis was prescribed. Results: We included 320,058 patient-days and 201,081 catheter-days across two haematology, two oncology and nine non-COVID-19 general medical wards. 669 HA-BSI occurred in 547 individual patients. In haematology patients, HA-BSI incidence was 9.1/1000 patient-days (95% CI 8.2–10.3). 224/299 (75%) of episodes were “unknown/other” source. Low virulence Gram-positive organisms (coagulase-negative staphylococci, viridans Streptococci, enterococci) accounted for 232/378 (61%) HA-BSI organisms and 46/52 (88%) CABSI organisms. Compared to oncology and general medical patients, haematology patients had higher HA-BSI incidence, but a smaller proportion of infections caused by virulent organisms (Gram-negative bacteria, Staphylococcus aureus, p < 0.01). Conclusions: In haematology patients, HA-BSI are less commonly caused by virulent Gram-negative organisms or Staphylococcus aureus compared to solid tumour and general medical patients, in the absence of quinolone prophylaxis.
- 9 April 2025
- Published by Springer Nature in Infection
- Vol. 53 (5) , 1-11
Open AccessEpidemiology of hospital-acquired bloodstream infections in haemato-oncology patients in Geneva, Switzerland
Background: Hospital-acquired bloodstream infections (HA-BSI), including catheter-associated bloodstream infections (CABSI), cause preventable harm in haemato-oncology patients but surveillance data are limited. Methods: We performed a retrospective cohort study using prospectively collected data in a large hospital network in Switzerland from 2017–2022. Incidence, source, and microbiology of HA-BSI were compared between (1) haematology patients with acute leukaemia or allogeneic stem cell transplantation (2) oncology patients with solid tumour or lymphoma, and (3) general medical patients. No routine quinolone prophylaxis was prescribed. Results: We included 320,058 patient-days and 201,081 catheter-days across two haematology, two oncology and nine non-COVID-19 general medical wards. 669 HA-BSI occurred in 547 individual patients. In haematology patients, HA-BSI incidence was 9.1/1000 patient-days (95% CI 8.2–10.3). 224/299 (75%) of episodes were “unknown/other” source. Low virulence Gram-positive organisms (coagulase-negative staphylococci, viridans Streptococci, enterococci) accounted for 232/378 (61%) HA-BSI organisms and 46/52 (88%) CABSI organisms. Compared to oncology and general medical patients, haematology patients had higher HA-BSI incidence, but a smaller proportion of infections caused by virulent organisms (Gram-negative bacteria, Staphylococcus aureus, p < 0.01). Conclusions: In haematology patients, HA-BSI are less commonly caused by virulent Gram-negative organisms or Staphylococcus aureus compared to solid tumour and general medical patients, in the absence of quinolone prophylaxis.
- Open Access
- 8 October 2024
- Published by Springer Nature in Antimicrobial Resistance & Infection Control
- Vol. 13 (1) , 1-6
Increase in PVC-BSI during the second COVID-19 pandemic year: analysis of catheter and patient characteristics
Background: Increasing nosocomial infections during the COVID-19 pandemic have been reported. However, data describing peripheral venous catheter associated bloodstream infections (PVC-BSI) are limited. Aims: To describe the epidemiology and risk factors for PVC-BSI during the COVID-19 pandemic. Methods: We conducted retrospective cohort study of prospectively collected PVC-BSI data in a 2100 bed hospital network in Switzerland. Adult patients with a PVC inserted between January 1, 2020 and December 31, 2021 were included. Risk factors for PVC-BSI were identified through descriptive analysis of patient and catheter characteristics, and univariable marginal Cox models. Results: 206,804 PVCs and 37 PVC-BSI were analysed. Most PVC-BSI were attributed to catheters inserted in the Emergency department (76%) or surgical wards (22%). PVC-BSI increased in 2021 compared to 2020 (hazard ratio 2021 vs. 2020 = 2.73; 95% confidence interval 1.19–6.29), with a numerically higher rate of Staphylococcus aureus (1/10, 10%, vs. 5/27, 19%) and polymicrobial infection (0/10, 0% vs. 4/27, 15%). PVC insertions, patient characteristics, and catheter characteristics remained similar across the study period. PVC-BSI risk was associated with admission to the intensive care unit (ICU), and use of wide gauge catheter ( < = 16G). Conclusion: Increased PVC-BSI during the COVID-19 pandemic was not explained by catheter or patient factors alone, and may result from system-wide changes. PVC-BSI events are primarily attributed to acute care settings, including the emergency department, surgical wards, and the ICU.
- 8 October 2024
- Published by Springer Nature in Antimicrobial Resistance & Infection Control
- Vol. 13 (1) , 1-6
Open AccessIncrease in PVC-BSI during the second COVID-19 pandemic year: analysis of catheter and patient characteristics
Background: Increasing nosocomial infections during the COVID-19 pandemic have been reported. However, data describing peripheral venous catheter associated bloodstream infections (PVC-BSI) are limited. Aims: To describe the epidemiology and risk factors for PVC-BSI during the COVID-19 pandemic. Methods: We conducted retrospective cohort study of prospectively collected PVC-BSI data in a 2100 bed hospital network in Switzerland. Adult patients with a PVC inserted between January 1, 2020 and December 31, 2021 were included. Risk factors for PVC-BSI were identified through descriptive analysis of patient and catheter characteristics, and univariable marginal Cox models. Results: 206,804 PVCs and 37 PVC-BSI were analysed. Most PVC-BSI were attributed to catheters inserted in the Emergency department (76%) or surgical wards (22%). PVC-BSI increased in 2021 compared to 2020 (hazard ratio 2021 vs. 2020 = 2.73; 95% confidence interval 1.19–6.29), with a numerically higher rate of Staphylococcus aureus (1/10, 10%, vs. 5/27, 19%) and polymicrobial infection (0/10, 0% vs. 4/27, 15%). PVC insertions, patient characteristics, and catheter characteristics remained similar across the study period. PVC-BSI risk was associated with admission to the intensive care unit (ICU), and use of wide gauge catheter ( < = 16G). Conclusion: Increased PVC-BSI during the COVID-19 pandemic was not explained by catheter or patient factors alone, and may result from system-wide changes. PVC-BSI events are primarily attributed to acute care settings, including the emergency department, surgical wards, and the ICU.